Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Schering
ANGELIQ SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): ANGELIQ Film-coated tablets COMPOSITION The pack contains 28 hormonal red film-coated tablets each with estradiol hemihydrate 1,033 mg (equivalent to estradiol 1,0 mg) and drospirenone 2,0 mg. PHARMACOLOGICAL CLASSIFICATION A. 21.8.2 Progesterones with estrogens. PHARMACOLOGICAL ACTION Pharmacodynamic properties Angeliq contains 17 beta-estradiol, which is chemically and biologically identical to endogenous human estradiol, and the synthetic progestogen, drospirenone. 17 beta-estradiol provides hormone replacement during and after the climacteric. The addition of drospirenone helps to provide bleeding control and opposes the development of endometrial hyperplasia caused by estrogens. • Effects of estradiol Estrogen substitution. • Effects of drospirenone Drospirenone exerts pharmacodynamic effects very similar to natural progesterone. Progestogenic activity Drospirenone is a progestogen with a central inhibitory effect on the hypothalamic-pituitary-gonadal axis. Antimineralocorticoid activity/antialdosterone activity Drospirenone displays antimineralocorticoid activity (similar to progesterone and spironolactone) affecting the renin- angiotensin-aldosterone system. Antiandrogenic activity Drospirenone has antiandrogenic properties. Effects on carbohydrate metabolism Drospirenone has no glucocorticoid or antiglucocorticoid activity and has no effect on glucose tolerance and insulin resistance. Glucose tolerance is not compromised by the use of Angeliq. Other properties Drospirenone is devoid of estrogenic or thyrotropic activity. Pharmacokinetic properties • Estradiol Absorption Following oral administration, estradiol is completely absorbed. During absorption and first liver passage, estradiol undergoes extensive metabolis Read the complete document